scholarly article | Q13442814 |
P356 | DOI | 10.1111/ENE.13466 |
P698 | PubMed publication ID | 28940893 |
P50 | author | Santiago Perez-Lloret | Q67389929 |
Arnaud Delval | Q41111578 | ||
Wassilios G. Meissner | Q41111597 | ||
F Tison | Q64856344 | ||
P2093 | author name string | A Destée | |
O Rascol | |||
P Derkinderen | |||
L Negre-Pages | |||
of the COPARK Study Group | |||
P Damier | |||
P2860 | cites work | Worsening of levodopa-induced dyskinesias by motor and mental tasks | Q28372142 |
Exenatide and the treatment of patients with Parkinson's disease | Q30540208 | ||
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature | Q34273182 | ||
Levodopa and the progression of Parkinson's disease | Q34553278 | ||
Levodopa-induced dyskinesias | Q34618170 | ||
Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance | Q37299382 | ||
SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures | Q37381351 | ||
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations | Q37716740 | ||
Classifying risk factors for dyskinesia in Parkinson's disease | Q37769643 | ||
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations | Q37898591 | ||
Wearing-off scales in Parkinson's disease: critique and recommendations | Q37903795 | ||
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. | Q40368066 | ||
Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life | Q40748733 | ||
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease | Q40860918 | ||
Falls in ambulatory non-demented patients with Parkinson's disease | Q41111540 | ||
Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort | Q41303725 | ||
Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study | Q43975400 | ||
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations | Q44742022 | ||
Impact of the motor complications of Parkinson's disease on the quality of life | Q45071670 | ||
Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease | Q45352049 | ||
Clinical determinants of health-related quality of life in Mexican patients with Parkinson's disease | Q45697484 | ||
Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. | Q46025359 | ||
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. | Q46834396 | ||
Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study | Q46875779 | ||
Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries | Q48072642 | ||
Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease | Q48076091 | ||
Quality of life in Parkinson's disease: the relative importance of the symptoms | Q48432774 | ||
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia | Q50249073 | ||
Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia | Q50263113 | ||
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. | Q51247357 | ||
Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. | Q51483415 | ||
Factors affecting the quality of life of patients with idiopathic Parkinson's disease--a cross-sectional study in an outpatient clinic attendees. | Q51926119 | ||
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. | Q53509756 | ||
PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. | Q53575895 | ||
Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. | Q53708979 | ||
P433 | issue | 12 | |
P921 | main subject | dyskinesia | Q629444 |
quality of life | Q13100823 | ||
P304 | page(s) | 1532-1538 | |
P577 | publication date | 2017-09-20 | |
P1433 | published in | European Journal of Neurology | Q15757256 |
P1476 | title | L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey | |
P478 | volume | 24 |
Q52562719 | Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease. |
Q50079431 | Dyskinesias and levodopa therapy: why wait? |
Q64968139 | Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia |
Q64096099 | Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease |
Q98290524 | Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease |
Q64901815 | Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. |
Search more.